Poly(I:C) as cancer vaccine adjuvant: Knocking on the door of medical breakthroughs

Pharmacology and Therapeutics

Volumn 146, Issue , 2015, Pages 120-131

  Ammi, Rachid ^a   De Waele, Jorrit ^a   Willemen, Yannick ^a   Van Brussel, Ilse ^a   Schrijvers, Dorien M ^a   Lion, Eva ^a,b   Smits, Evelien L J ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Adjuvant; Anti tumor immunity; Cancer vaccine; Poly(I:C); Poly ICLC; TLR

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; POLYINOSINIC POLYCYTIDYLIC ACID; CARBOXYMETHYLCELLULOSE; IMMUNOLOGICAL ADJUVANT; POLYLYSINE;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR MODEL; ANALOGS AND DERIVATIVES; ANIMAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CARBOXYMETHYLCELLULOSE SODIUM; HUMANS; POLY I-C; POLYLYSINE;

EID: 84921289568     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2014.09.010     Document Type: Review

References (116)

1. M.T. Abreu Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function Nat Rev Immunol 10 2 2010 131 144 10.1038/nri2707
2. T. Akazawa, T. Ebihara, M. Okuno, Y. Okuda, M. Shingai, and K. Tsujimura Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells Proc Natl Acad Sci U S A 104 1 2007 252 257 10.1073/pnas.0605978104
3. F. Aranda, D. Llopiz, N. Diaz-Valdes, J.I. Riezu-Boj, J. Bezunartea, and M. Ruiz Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors Cancer Res 71 9 2011 3214 3224 10.1158/0008-5472.can-10-3259
4. K. Babiarova, L. Kutinova, K. Zurkova, J. Krystofova, E. Brabcova, and P. Hainz Immunization with WT1-derived peptides by tattooing inhibits the growth of TRAMP-C2 prostate tumor in mice J Immunother 35 6 2012 478 487 10.1097/CJI.0b013e3182618381
5. A. Banz, M. Cremel, A. Mouvant, N. Guerin, F. Horand, and Y. Godfrin Tumor growth control using red blood cells as the antigen delivery system and poly(I:C) J Immunother 35 5 2012 409 417 10.1097/CJI.0b013e3182594352
6. R.K. Benwell, J.E. Hruska, K.L. Fritsche, and D.R. Lee Double stranded RNA- relative to other TLR ligand-activated dendritic cells induce extremely polarized human Th1 responses Cell Immunol 264 2 2010 119 126 10.1016/j.cellimm.2010.05.008
7. R. Besch, H. Poeck, T. Hohenauer, D. Senft, G. Hacker, and C. Berking Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells J Clin Invest 119 8 2009 2399 2411 10.1172/JCI37155
8. P. Bhoopathi, B.A. Quinn, Q. Gui, X.N. Shen, S.R. Grossman, and S.K. Das Pancreatic cancer-specific cell death induced in vivo by cytoplasmic-delivered polyinosine-polycytidylic acid Cancer Res 2014 10.1158/0008-5472.CAN-14-0819
9. J.M. Brewer (How) do aluminium adjuvants work? Immunol Lett 102 1 2006 10 15 10.1016/j.imlet.2005.08.002
10. A.H. Broquet, Y. Hirata, C.S. McAllister, and M.F. Kagnoff RIG-I/MDA5/MAVS are required to signal a protective IFN response in rotavirus-infected intestinal epithelium J Immunol 186 3 2011 1618 1626 10.4049/jimmunol.1002862
11. K.J. Champney, D.P. Levine, H.B. Levy, and A.M. Lerner Modified polyriboinosinic-polyribocytidylic acid complex: sustained interferonemia and its physiological associates in humans Infect Immun 25 3 1979 831 837
12. M.A. Cheever Twelve immunotherapy drugs that could cure cancers Immunol Rev 222 2008 357 368 10.1111/j.1600-065X.2008.00604.x
13. S. Chen, R. Ou, J. Tang, X. Deng, Y. Wu, and J.C. van Velkinburgh Enhanced anti-tumor effects of HPV16E7(49-57)-based vaccine by combined immunization with poly(I:C) and oxygen-regulated protein 150 Cancer Epidemiol 37 2 2013 172 178 10.1016/j.canep.2012.10.005
14. Y.S. Cheng, and F. Xu Anticancer function of polyinosinic-polycytidylic acid Cancer Biol Ther 10 12 2010 1219 1223
15. H.I. Cho, K. Barrios, Y.R. Lee, A.K. Linowski, and E. Celis BiVax: a peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses Cancer Immunol Immunother 62 4 2013 787 799 10.1007/s00262-012-1382-6
16. H.I. Cho, and E. Celis Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects Cancer Res 69 23 2009 9012 9019 10.1158/0008-5472.CAN-09-2019
17. E.I. Cho, C. Tan, G.K. Koski, P.A. Cohen, S. Shu, and W.T. Lee Toll-like receptor agonists as third signals for dendritic cell-tumor fusion vaccines Head Neck 32 6 2010 700 707 10.1002/hed.21241
18. R.L. Coffman, A. Sher, and R.A. Seder Vaccine adjuvants: putting innate immunity to work Immunity 33 4 2010 492 503 10.1016/j.immuni.2010.10.002
19. Z. Cui, U.M. Le, F. Qiu, and D.S. Shaker Learning from viruses: the necrotic bodies of tumor cells with intracellular synthetic dsRNA induced strong anti-tumor immune responses Pharm Res 24 9 2007 1645 1652 10.1007/s11095-007-9293-5
20. Z. Cui, and F. Qiu Synthetic double-stranded RNA poly(I:C) as a potent peptide vaccine adjuvant: therapeutic activity against human cervical cancer in a rodent model Cancer Immunol Immunother 55 10 2006 1267 1279 10.1007/s00262-005-0114-6
21. S.K. Datta, V. Redecke, K.R. Prilliman, K. Takabayashi, M. Corr, and T. Tallant A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells J Immunol 170 8 2003 4102 4110
22. J. Delaloye, T. Roger, Q.G. Steiner-Tardivel, D. Le Roy, M. Knaup Reymond, and S. Akira Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome PLoS Pathog 5 6 2009 e1000480 10.1371/journal.ppat.1000480
23. M.V. Dhodapkar, M. Sznol, B. Zhao, D. Wang, R.D. Carvajal, and M.L. Keohan Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205 Sci Transl Med 6 232 2014 232ra251 10.1126/scitranslmed.3008068
24. S. Domingos-Pereira, L. Decrausaz, L. Derre, M. Bobst, P. Romero, and J.T. Schiller Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice Mucosal Immunol 6 2 2013 393 404 10.1038/mi.2012.83
25. T.W. Dubensky Jr., and S.G. Reed Adjuvants for cancer vaccines Semin Immunol 22 3 2010 155 161 10.1016/j.smim.2010.04.007
26. V. Durand, S.Y. Wong, D.F. Tough, and A. Le Bon IFN-alpha/beta-dependent cross-priming induced by specific toll-like receptor agonists Vaccine 24 Suppl. 2 2006 (S2-22-23)
27. A.D. Edwards, S.S. Diebold, E.M. Slack, H. Tomizawa, H. Hemmi, and T. Kaisho Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 alpha+ DC correlates with unresponsiveness to imidazoquinolines Eur J Immunol 33 4 2003 827 833 10.1002/eji.200323797
28. C.H. Ewel, W.J. Urba, W.C. Kopp, J.W. Smith II, R.G. Steis, and J.L. Rossio Polyinosinic-polycytidylic acid complexed with poly-l-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects Cancer Res 52 11 1992 3005 3010
29. S. Feldman, W.T. Hughes, R.W. Darlington, and H.K. Kim Evaluation of topical polyinosinic acid-polycytidylic acid in treatment of localized herpes zoster in children with cancer: a randomized, double-blind controlled study Antimicrob Agents Chemother 8 3 1975 289 294
30. N. Fitzner, S. Clauberg, F. Essmann, J. Liebmann, and V. Kolb-Bachofen Human skin endothelial cells can express all 10 TLR genes and respond to respective ligands Clin Vaccine Immunol 15 1 2008 138 146 10.1128/CVI.00257-07
31. D. Frleta, C.I. Yu, E. Klechevsky, A.L. Flamar, G. Zurawski, and J. Banchereau Influenza virus and poly(I:C) inhibit MHC class I-restricted presentation of cell-associated antigens derived from infected dead cells captured by human dendritic cells J Immunol 182 5 2009 2766 2776 10.4049/jimmunol.0801720
32. F. Guo, C.K. Chang, H.H. Fan, X.X. Nie, Y.N. Ren, and Y.Y. Liu Anti-tumour effects of exosomes in combination with cyclophosphamide and polyinosinic-polycytidylic acid J Int Med Res 36 6 2008 1342 1353
33. A.M. Hafner, B. Corthesy, and H.P. Merkle Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant Adv Drug Deliv Rev 65 10 2013 1386 1399 10.1016/j.addr.2013.05.013
34. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 5 2011 646 674 10.1016/j.cell.2011.02.013
35. M.L. Hanke, and T. Kielian Toll-like receptors in health and disease in the brain: mechanisms and therapeutic potential Clin Sci (Lond) 121 9 2011 367 387 10.1042/CS20110164
36. J. Hansen, T. Lindenstrom, J. Lindberg-Levin, C. Aagaard, P. Andersen, and E.M. Agger CAF05: cationic liposomes that incorporate synthetic cord factor and poly(I:C) induce CTL immunity and reduce tumor burden in mice Cancer Immunol Immunother 61 6 2012 893 903 10.1007/s00262-011-1156-6
37. F. Hayashi, T.K. Means, and A.D. Luster Toll-like receptors stimulate human neutrophil function Blood 102 7 2003 2660 2669 10.1182/blood-2003-04-1078
38. S. Heinz, V. Haehnel, M. Karaghiosoff, L. Schwarzfischer, M. Muller, and S.W. Krause Species-specific regulation of Toll-like receptor 3 genes in men and mice J Biol Chem 278 24 2003 21502 21509 10.1074/jbc.M301476200
39. H.W. Herr, N. Kemeny, A. Yagoda, and W.F. Whitmore Jr. Poly I:C immunotherapy in patients with papillomas or superficial carcinomas of the bladder Natl Cancer Inst Monogr 49 1978 325
40. J. Hiscott, T.L. Nguyen, M. Arguello, P. Nakhaei, and S. Paz Manipulation of the nuclear factor-kappaB pathway and the innate immune response by viruses Oncogene 25 51 2006 6844 6867 10.1038/sj.onc.1209941
41. V. Hornung, S. Rothenfusser, S. Britsch, A. Krug, B. Jahrsdorfer, and T. Giese Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides J Immunol 168 9 2002 4531 4537
42. Y.K. Huang, Z. Zheng, and F. Qiu Polyinosinic-cytidylic acid as an adjuvant on natural killer- and dendritic cell-mediated antitumor activities Tumour Biol 34 3 2013 1615 1623 10.1007/s13277-013-0693-3
43. H. Ikeda, K. Chamoto, T. Tsuji, Y. Suzuki, D. Wakita, and T. Takeshima The critical role of type-1 innate and acquired immunity in tumor immunotherapy Cancer Sci 95 9 2004 697 703
44. D. Kabelitz Expression and function of Toll-like receptors in T lymphocytes Curr Opin Immunol 19 1 2007 39 45 10.1016/j.coi.2006.11.007
45. P. Kalinski, Y. Nakamura, P. Watchmaker, A. Giermasz, R. Muthuswamy, and R.B. Mailliard Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines Immunol Res 36 1-3 2006 137 146 10.1385/IR:36:1:137
46. T. Kimura, J.R. McKolanis, L.A. Dzubinski, K. Islam, D.M. Potter, and A.M. Salazar MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study Cancer Prev Res (Phila) 6 1 2013 18 26 10.1158/1940-6207.capr-12-0275
47. A. Koarai, S. Yanagisawa, H. Sugiura, T. Ichikawa, K. Akamatsu, and T. Hirano Cigarette smoke augments the expression and responses of toll-like receptor 3 in human macrophages Respirology 17 6 2012 1018 1025 10.1111/j.1440-1843.2012.02198.x
48. E. Kovalcsik, K. Lowe, M. Fischer, A. Dalgleish, and M.D. Bodman-Smith Poly(I:C)-induced tumour cell death leads to DC maturation and Th1 activation Cancer Immunol Immunother 60 11 2011 1609 1624 10.1007/s00262-011-1058-7
49. K. Kubler, C. tho Pesch, N. Gehrke, S. Riemann, J. Dassler, and C. Coch Immunogenic cell death of human ovarian cancer cells induced by cytosolic poly(I:C) leads to myeloid cell maturation and activates NK cells Eur J Immunol 41 10 2011 3028 3039 10.1002/eji.201141555
50. A.M. Kvarnhammar, T. Petterson, and L.O. Cardell NOD-like receptors and RIG-I-like receptors in human eosinophils: activation by NOD1 and NOD2 agonists Immunology 134 3 2011 314 325 10.1111/j.1365-2567.2011.03492.x
51. B.C. Lampkin, A.S. Levine, H. Levy, W. Krivit, and D. Hammond Phase II trial of a complex polyriboinosinic-polyribocytidylic acid with poly-l-lysine and carboxymethyl cellulose in the treatment of children with acute leukemia and neuroblastoma: a report from the Children's Cancer Study Group Cancer Res 45 11 Pt 2 1985 5904 5909
52. N.M. Lauzon, F. Mian, R. MacKenzie, and A.A. Ashkar The direct effects of Toll-like receptor ligands on human NK cell cytokine production and cytotoxicity Cell Immunol 241 2 2006 102 112 10.1016/j.cellimm.2006.08.004
53. A.S. Levine, M. Sivulich, P.H. Wiernik, and H.B. Levy Initial clinical trials in cancer patients of polyriboinosinic-polyribocytidylic acid stabilized with poly-l-lysine, in carboxymethylcellulose [poly(ICLC)], a highly effective interferon inducer Cancer Res 39 5 1979 1645 1650
54. H.B. Levy, G. Baer, S. Baron, C.E. Buckler, C.J. Gibbs, and M.J. Iadarola A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates J Infect Dis 132 4 1975 434 439
55. E. Lion, S. Anguille, Z.N. Berneman, E.L. Smits, and V.F. Van Tendeloo Poly(I:C) enhances the susceptibility of leukemic cells to NK cell cytotoxicity and phagocytosis by DC PLoS One 6 6 2011 e20952 10.1371/journal.pone.0020952
56. E. Lion, E.L. Smits, Z.N. Berneman, and V.F. Van Tendeloo Acute myeloid leukemic cell lines loaded with synthetic dsRNA trigger IFN-gamma secretion by human NK cells Leuk Res 33 4 2009 539 546 10.1016/j.leukres.2008.08.020
57. E. Lion, E.L. Smits, Z.N. Berneman, and V.F. Van Tendeloo NK cells: key to success of DC-based cancer vaccines? Oncologist 17 10 2012 1256 1270 10.1634/theoncologist.2011-0122 (theoncologist.2011-0122 [pii])
58. D. Llopiz, J. Dotor, A. Zabaleta, J.J. Lasarte, J. Prieto, and F. Borras-Cuesta Combined immunization with adjuvant molecules poly(I:C) and anti-CD40 plus a tumor antigen has potent prophylactic and therapeutic antitumor effects Cancer Immunol Immunother 57 1 2008 19 29 10.1007/s00262-007-0346-8
59. M.P. Longhi, C. Trumpfheller, J. Idoyaga, M. Caskey, I. Matos, and C. Kluger Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant J Exp Med 206 7 2009 1589 1602 10.1084/jem.20090247
60. A.E. Maluish, J.W. Reid, E.A. Crisp, W.R. Overton, H. Levy, and K.A. Foon Immunomodulatory effects of poly(I, C)-LC in cancer patients J Biol Response Mod 4 6 1985 656 663
61. C. Mansilla, P. Berraondo, M. Durantez, M. Martinez, N. Casares, and L. Arribillaga Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin Int J Cancer 131 3 2012 641 651 10.1002/ijc.26412
62. J.C. Marsh, J. Goldfarb, T.D. Shafman, and A.Z. Diaz Current status of immunotherapy and gene therapy for high-grade gliomas Cancer Control 20 1 2013 43 48
63. J. Martinez, X. Huang, and Y. Yang Direct TLR2 signaling is critical for NK cell activation and function in response to vaccinia viral infection PLoS Pathog 6 3 2010 e1000811 10.1371/journal.ppat.1000811
64. S. McBride, K. Hoebe, P. Georgel, and E. Janssen Cell-associated double-stranded RNA enhances antitumor activity through the production of type I IFN J Immunol 177 9 2006 6122 6128
65. S. McCartney, W. Vermi, S. Gilfillan, M. Cella, T.L. Murphy, and R.D. Schreiber Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells J Exp Med 206 13 2009 2967 2976 10.1084/jem.20091181
66. A. Moretta, E. Marcenaro, S. Parolini, G. Ferlazzo, and L. Moretta NK cells at the interface between innate and adaptive immunity Cell Death Differ 15 2 2008 226 233 10.1038/sj.cdd.4402170
67. M.A. Morse, R. Chapman, J. Powderly, K. Blackwell, T. Keler, and J. Green Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients Clin Cancer Res 17 14 2011 4844 4853 10.1158/1078-0432.ccr-11-0891
68. M. Muzio, D. Bosisio, N. Polentarutti, G. D'Amico, A. Stoppacciaro, and R. Mancinelli Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells J Immunol 164 11 2000 5998 6004
69. H. Nagase, S. Okugawa, Y. Ota, M. Yamaguchi, H. Tomizawa, and K. Matsushima Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand J Immunol 171 8 2003 3977 3982
70. T. Nakamura, R. Moriguchi, K. Kogure, and H. Harashima Incorporation of polyinosine-polycytidylic acid enhances cytotoxic T cell activity and antitumor effects by octaarginine-modified liposomes encapsulating antigen, but not by octaarginine-modified antigen complex Int J Pharm 441 1-2 2013 476 481 10.1016/j.ijpharm.2012.11.006
71. O. Nakamura, N. Shitara, M. Matsutani, K. Takakura, and H. Machida Phase I-II trials of poly(ICLC) in malignant brain tumor patients J Interferon Res 2 1 1982 1 4
72. G. Napolitani, A. Rinaldi, F. Bertoni, F. Sallusto, and A. Lanzavecchia Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells Nat Immunol 6 8 2005 769 776 10.1038/ni1223
73. N. Nomi, S. Kodama, and M. Suzuki Toll-like receptor 3 signaling induces apoptosis in human head and neck cancer via survivin associated pathway Oncol Rep 24 1 2010 225 231
74. H. Okada, L.H. Butterfield, M. Sakaki, A. Hoji, A.M. Salazar, and E.G. Shaw Abstract LB-135: a pilot study of peptide-based vaccines in combination with poly ICLC in patients with WHO grade 2 low-grade glioma Paper presented at the American Association for Cancer Research, Chicago, IL 2012
75. H. Okada, P. Kalinski, R. Ueda, A. Hoji, G. Kohanbash, and T.E. Donegan Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma J Clin Oncol 29 3 2011 330 336 10.1200/jco.2010.30.7744
76. A. Paone, D. Starace, R. Galli, F. Padula, P. De Cesaris, and A. Filippini Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism Carcinogenesis 29 7 2008 1334 1342 10.1093/carcin/bgn149
77. J.S. Park, H.S. Kim, H.M. Park, C.H. Kim, and T.G. Kim Efficient induction of anti-tumor immunity by a TAT-CEA fusion protein vaccine with poly(I:C) in a murine colorectal tumor model Vaccine 29 47 2011 8642 8648 10.1016/j.vaccine.2011.09.052
78. K.S. Parsons, A.C. Hsu, and P.A. Wark TLR3 and MDA5 signalling, although not expression, is impaired in asthmatic epithelial cells in response to rhinovirus infection Clin Exp Allergy 44 1 2014 91 101 10.1111/cea.12218
79. P. Parvizi, A.I. Mallick, K. Haq, H.R. Haghighi, S. Orouji, and N. Thanthrige-Don A toll-like receptor 3 ligand enhances protective effects of vaccination against Marek's disease virus and hinders tumor development in chickens Viral Immunol 25 5 2012 394 401 10.1089/vim.2012.0033
80. R. Perret, S.R. Sierro, N.K. Botelho, S. Corgnac, A. Donda, and P. Romero Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells enhance tumor immunity Cancer Res 73 22 2013 6597 6608 10.1158/0008-5472.CAN-13-0875
81. A. Pichlmair, and C. Reis e Sousa Innate recognition of viruses Immunity 27 3 2007 370 383 10.1016/j.immuni.2007.08.012
82. S. Pisegna, G. Pirozzi, M. Piccoli, L. Frati, A. Santoni, and G. Palmieri p38 MAPK activation controls the TLR3-mediated up-regulation of cytotoxicity and cytokine production in human NK cells Blood 104 13 2004 4157 4164 10.1182/blood-2004-05-1860
83. I.F. Pollack, R.I. Jakacki, L.H. Butterfield, and H. Okada Abstract LB-131: peptide vaccine therapy for childhood gliomas: interim results of a pilot study Paper presented at the American Association for Cancer Research, Chicago, IL 2012
84. J.L. Pooley, W.R. Heath, and K. Shortman Cutting edge: intravenous soluble antigen is presented to CD4 T cells by CD8- dendritic cells, but cross-presented to CD8 T cells by CD8+ dendritic cells J Immunol 166 9 2001 5327 5330
85. R.M. Prins, H. Soto, V. Konkankit, S.K. Odesa, A. Eskin, and W.H. Yong Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy Clin Cancer Res 17 6 2011 1603 1615 10.1158/1078-0432.ccr-10-2563
86. V. Pulko, X. Liu, C.J. Krco, K.J. Harris, X. Frigola, and E.D. Kwon TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination J Immunol 183 6 2009 3634 3641 10.4049/jimmunol.0900974
87. M.A. Rettenmaier, M.L. Berman, and P.J. DiSaia Treatment of advanced ovarian cancer with polyinosinic-polycytidylic lysine carboxymethylcellulose (poly(ICLC)) Gynecol Oncol 24 3 1986 359 361
88. R.A. Robinson, V.T. DeVita, H.B. Levy, S. Baron, S.P. Hubbard, and A.S. Levine A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors J Natl Cancer Inst 57 3 1976 599 602
89. P. Sabbatini, T. Tsuji, L. Ferran, E. Ritter, C. Sedrak, and K. Tuballes Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients Clin Cancer Res 18 23 2012 6497 6508 10.1158/1078-0432.ccr-12-2189
90. B. Salaun, I. Coste, M.C. Rissoan, S.J. Lebecque, and T. Renno TLR3 can directly trigger apoptosis in human cancer cells J Immunol 176 8 2006 4894 4901
91. A.M. Salazar, H.B. Levy, S. Ondra, M. Kende, B. Scherokman, and D. Brown Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study Neurosurgery 38 6 1996 1096 1103 (discussion 1103-1094)
92. M.L. Salem, C.M. Diaz-Montero, S.A. El-Naggar, Y. Chen, O. Moussa, and D.J. Cole The TLR3 agonist poly(I:C) targets CD8+ T cells and augments their antigen-specific responses upon their adoptive transfer into naive recipient mice Vaccine 27 4 2009 549 557 10.1016/j.vaccine.2008.11.013
93. M.L. Salem, S.A. El-Naggar, A. Kadima, W.E. Gillanders, and D.J. Cole The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu Vaccine 24 24 2006 5119 5132 10.3201/eid1204.050599
94. M.L. Salem, A.N. Kadima, D.J. Cole, and W.E. Gillanders Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity J Immunother 28 3 2005 220 228
95. Y. Sato, Y. Goto, N. Narita, and D.S. Hoon Cancer cells expressing Toll-like receptors and the tumor microenvironment Cancer Microenviron 2 Suppl. 1 2009 205 214 10.1007/s12307-009-0022-y
96. J. Sawaki, H. Tsutsui, N. Hayashi, K. Yasuda, S. Akira, and T. Tanizawa Type 1 cytokine/chemokine production by mouse NK cells following activation of their TLR/MyD88-mediated pathways Int Immunol 19 3 2007 311 320 10.1093/intimm/dxl148
97. K.N. Schmidt, B. Leung, M. Kwong, K.A. Zarember, S. Satyal, and T.A. Navas APC-independent activation of NK cells by the Toll-like receptor 3 agonist double-stranded RNA J Immunol 172 1 2004 138 143
98. O. Schulz, S.S. Diebold, M. Chen, T.I. Naslund, M.A. Nolte, and L. Alexopoulou Toll-like receptor 3 promotes cross-priming to virus-infected cells Nature 433 7028 2005 887 892 10.1038/nature03326
99. T.F. Schwarz Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix Adv Ther 26 11 2009 983 998 10.1007/s12325-009-0079-5
100. A. Shanker, and F.M. Marincola Cooperativity of adaptive and innate immunity: implications for cancer therapy Cancer Immunol Immunother 60 8 2011 1061 1074 10.1007/s00262-011-1053-z
101. S. Sivori, M. Falco, M. Della Chiesa, S. Carlomagno, M. Vitale, and L. Moretta CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells Proc Natl Acad Sci U S A 101 27 2004 10116 10121 10.1073/pnas.0403744101
102. E.L. Smits, N. Cools, E. Lion, K. Van Camp, P. Ponsaerts, and Z.N. Berneman The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells Cancer Immunol Immunother 59 1 2010 35 46 10.1007/s00262-009-0721-8
103. E.L. Smits, P. Ponsaerts, A.L. Van de Velde, A. Van Driessche, N. Cools, and M. Lenjou Proinflammatory response of human leukemic cells to dsRNA transfection linked to activation of dendritic cells Leukemia 21 8 2007 1691 1699 10.1038/sj.leu.2404763
104. D. Tormo, A. Ferrer, P. Bosch, E. Gaffal, E. Basner-Tschakarjan, and J. Wenzel Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice Cancer Res 66 10 2006 5427 5435 10.1158/0008-5472.can-06-0399
105. T. Tsuji, P. Sabbatini, A.A. Jungbluth, E. Ritter, L. Pan, and G. Ritter Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial Cancer Immunol Res 1 5 2013 340 350 10.1158/2326-6066.CIR-13-0089
106. S. Uematsu, and S. Akira Toll-like receptors and Type I interferons J Biol Chem 282 21 2007 15319 15323 10.1074/jbc.R700009200
107. R.M. Verdijk, T. Mutis, B. Esendam, J. Kamp, C.J. Melief, and A. Brand Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells J Immunol 163 1 1999 57 61
108. C. Wang, Y. Zhuang, Y. Zhang, Z. Luo, N. Gao, and P. Li Toll-like receptor 3 agonist complexed with cationic liposome augments vaccine-elicited antitumor immunity by enhancing TLR3-IRF3 signaling and type I interferons in dendritic cells Vaccine 30 32 2012 4790 4799 10.1016/j.vaccine.2012.05.027
109. D.A. Wick, S.D. Martin, B.H. Nelson, and J.R. Webb Profound CD8+ T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly(I:C) Vaccine 29 5 2011 984 993 10.1016/j.vaccine.2010.11.036
110. H. Xiao, Y. Peng, Y. Hong, L. Huang, Z.S. Guo, and D.L. Bartlett Local administration of TLR ligands rescues the function of tumor-infiltrating CD8 T cells and enhances the antitumor effect of lentivector immunization J Immunol 190 11 2013 5866 5873 10.4049/jimmunol.1203470
111. I. Zanoni, F. Granucci, M. Foti, and P. Ricciardi-Castagnoli Self-tolerance, dendritic cell (DC)-mediated activation and tissue distribution of natural killer (NK) cells Immunol Lett 110 1 2007 6 17 10.1016/j.imlet.2007.03.001
112. X. Zhao, M. Ai, Y. Guo, X. Zhou, L. Wang, and X. Li Poly I:C-induced tumor cell apoptosis mediated by pattern-recognition receptors Cancer Biother Radiopharm 27 9 2012 530 534 10.1089/cbr.2012.1226
113. R. Zheng, P.A. Cohen, C.A. Paustian, T.D. Johnson, W.T. Lee, and S. Shu Paired Toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12 Cancer Res 68 11 2008 4045 4049 10.1158/0008-5472.can-07-6669
114. M. Zhou, M.M. McFarland-Mancini, H.M. Funk, N. Husseinzadeh, T. Mounajjed, and A.F. Drew Toll-like receptor expression in normal ovary and ovarian tumors Cancer Immunol Immunother 58 9 2009 1375 1385 10.1007/s00262-008-0650-y
115. X. Zhu, F. Nishimura, K. Sasaki, M. Fujita, J.E. Dusak, and J. Eguchi Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models J Transl Med 5 2007 10 10.1186/1479-5876-5-10
116. X. Zhu, F. Nishimura, K. Sasaki, M. Fujita, J.E. Dusak, and J. Eguchi Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models J Transl Med 5 2007 10 10.1186/1479-5876-5-10